Although pharmacological targeting of PDGFR in human PAH was associated with severe adverse events and significant side-effects [62], there are several emerging strategies to successfully block PDGF signaling either upstream (anti-PDGF antibodies [63]) or downstream of PDGFR (mTOR and Akt inhibitors) [26,37,40]. Here, MTOR is linked to pulmonary arterial hypertension.